Scilex Holding Company
$6.95
▲
7.67%
2026-04-21 09:19:01
www.scilexholding.com
NCM: SCLX
Explore Scilex Holding Company stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$58.97 M
Current Price
$6.95
52W High / Low
$34.27 / $3.6
Stock P/E
—
Book Value
$-29.75
Dividend Yield
—
ROCE
55.67%
ROE
39.83%
Face Value
—
EPS
$-40.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
—
Beta
—
Debt / Equity
-0.2
Current Ratio
0.08
Quick Ratio
0.15
Forward P/E
9.32
Price / Sales
1.58
Enterprise Value
$175.33 M
EV / EBITDA
-0.66
EV / Revenue
5.8
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biogen Inc. | $191.44 | 21.83 | $28.09 B | — | 9.46% | 7.39% | $202.41 / $114.66 | $124.36 |
| 2. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 3. | MIRA Pharmaceuticals, Inc. | $1.12 | — | $47.06 M | — | -100.98% | -1.66% | $2.45 / $0.83 | $0.25 |
| 4. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
| 5. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 6. | Novartis AG | $147.76 | 20.66 | $301.93 B | 3.13% | 21.09% | 30.81% | $131 / $87.89 | $24.18 |
| 7. | Merck & Co., Inc. | $112.83 | 15.49 | $278.33 B | 2.9% | 20.37% | 36.88% | $125.14 / $73.31 | $21.26 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 10.56 M | 9.9 M | 5 M | 14.9 M | 14.44 M |
| Operating Profit | -186.51 M | -20.41 M | -27.9 M | -28.38 M | -22.42 M |
| Net Profit | -257.23 M | -42.31 M | -26.08 M | -6.46 M | -4.39 M |
| EPS in Rs | -36.58 | -6.02 | -3.71 | -0.92 | -0.62 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 56.59 M | 46.74 M | 38.03 M | 31.32 M |
| Operating Profit | -92.79 M | -105.43 M | -50.63 M | -35.84 M |
| Net Profit | -72.81 M | -114.33 M | -23.36 M | -88.42 M |
| EPS in Rs | -10.35 | -16.26 | -3.32 | -12.57 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 92.95 M | 101.31 M | 86.53 M | 77.93 M |
| Total Liabilities | 285.59 M | 274.25 M | 50.29 M | 301.81 M |
| Equity | -192.64 M | -172.94 M | 36.24 M | -223.88 M |
| Current Assets | 41.55 M | 46.78 M | 29.61 M | 23 M |
| Current Liabilities | 259.63 M | 250.38 M | 44.84 M | 169.42 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | 19.35 M | -20.71 M | -21.26 M | -28.66 M |
| Investing CF | -2.67 M | -0.33 M | -2.07 M | 0 M |
| Financing CF | -18.13 M | 23.58 M | 21.17 M | 28.16 M |
| Free CF | 18.75 M | -21.04 M | -23.32 M | -28.66 M |
| Capex | -0.6 M | -0.33 M | -2.07 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 21.07% | 22.9% | 21.45% | — |
| Earnings Growth % | 36.32% | -389.35% | 73.58% | — |
| Profit Margin % | -128.66% | -244.59% | -61.43% | -282.35% |
| Operating Margin % | -163.96% | -225.55% | -133.13% | -114.44% |
| Gross Margin % | 70.51% | 66.45% | 71.61% | 88.4% |
| EBITDA Margin % | -118.04% | -233.41% | -25.75% | -143.3% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-15 | 1:0.0285714 |